An integrated prognostic classifier for Stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers

Journal of Thoracic Oncology

Volumn 10, Issue 7, 2015, Pages 1037-1048

  Robles, Ana I ^a   Arai, Eri ^b   Mathé, Ewy A ^a   Okayama, Hirokazu ^a   Schetter, Aaron J ^a   Brown, Derek ^a   Petersen, David ^a   Bowman, Elise D ^a   Noro, Rintaro ^a   Welsh, Judith A ^a   Edelman, Daniel C ^a   Stevenson, Holly S ^a   Wang, Yonghong ^a   Tsuchiya, Naoto ^b   Kohno, Takashi ^b   Skaug, Vidar ^c   Mollerup, Steen ^c   Haugen, Aage ^c   Meltzer, Paul S ^a   Yokota, Jun ^d   Kanai, Yae ^b   Harris, Curtis C ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

^d Institute of Predictive and Personalized Medicine of Cancer IMPPC   (Spain)

Author keywords

Adenocarcinoma; NSCLC; Precision medicine; Prognosis; Stage I

Indexed keywords

BIOLOGICAL MARKER; GENOMIC DNA; MESSENGER RNA; MICRORNA; POLYCOMB GROUP PROTEIN; TRANSCRIPTION FACTOR HOXA9; TUMOR MARKER;

ACCURACY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CHROMATIN; CLASSIFIER; DNA METHYLATION; EMBRYONIC STEM CELL; FEMALE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PRECISION MEDICINE; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; ADENOCARCINOMA; COHORT ANALYSIS; DNA MICROARRAY; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; PROCEDURES; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COHORT STUDIES; DNA METHYLATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECISION MEDICINE; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 84942932334     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000560     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D., Global cancer statistics. CA Cancer J Clin 2011 61 69 90
2. Siegel R, Ma J, Zou Z, Jemal A., Cancer statistics, 2014. CA Cancer J Clin 2014 64 9 29
3. Aberle DR, Adams AM, Berg CD, Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011 365 395 409
4. National Comprehensive Cancer Network Non-small-cell lung cancer (Version 4.2014). Available at http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed October 9, 2014
5. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P, International Staging Committee and Participating Institutions The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009 4 792 801
6. Subramanian J, Simon R., What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol 2010 7 327 334
7. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014 511 543 550
8. Saito M, Schetter AJ, Mollerup S, The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011 17 1875 1882
9. Akagi I, Okayama H, Schetter AJ, Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res 2013 73 3821 3832
10. Okayama H, Schetter AJ, Ishigame T, The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol Biomarkers Prev 2014 23 2884 2894
11. Baylin SB, Jones PA., A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011 11 726 734
12. Sato T, Arai E, Kohno T, Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: its correlation with smoking history and chronic obstructive pulmonary disease. Int J Cancer 2014 135 319 334
13. Hawes SE, Stern JE, Feng Q, DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. Lung Cancer 2010 69 172 179
14. Carvalho RH, Hou J, Haberle V, Genomewide DNA methylation analysis identifies novel methylated genes in non-small-cell lung carcinomas. J Thorac Oncol 2013 8 562 573
15. Selamat SA, Galler JS, Joshi AD, DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One 2011 6 e21443
16. Sato T, Arai E, Kohno T, DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma. PLoS One 2013 8 e59444
17. Walter K, Holcomb T, Januario T, DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res 2012 18 2360 2373
18. Shinjo K, Okamoto Y, An B, Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis 2012 33 1277 1285
19. Brock MV, Hooker CM, Ota-Machida E, DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008 358 1118 1128
20. Sandoval J, Mendez-Gonzalez J, Nadal E, A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol 2013 31 4140 4147
21. McShane LM, Hayes DF., Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol 2012 30 4223 4232
22. Subramanian J, Simon R., Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010 102 464 474
23. Huang da W, Sherman BT, Lempicki RA., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009 4 44 57
24. Hess KR., Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995 14 1707 1723
25. Edgar R, Domrachev M, Lash AE., Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002 30 207 210
26. Ben-Porath I, Thomson MW, Carey VJ, An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008 40 499 507
27. Easwaran H, Johnstone SE, Van Neste L, A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012 22 837 849
28. Kikuchi J, Kinoshita I, Shimizu Y, Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 2010 116 3015 3024
29. Huqun, Ishikawa R, Zhang J, Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 2012 118 1599 1606
30. Behrens C, Solis LM, Lin H, EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res 2013 19 6556 6565
31. Shedden K, Taylor JM, Enkemann SA, Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008 14 822 827
32. Sugimura H, Nichols FC, Yang P, Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007 83 409 17; discussion 417
33. National Research Council (US) Committee on a Framework for Developing a New Taxonomy of Disease Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 2011 Washington (DC) National Academies Press (US). Available at: http://www.ncbi.nlm.nih.gov/books/NBK91503/. Accessed June 12, 2013.
34. Seike M, Yanaihara N, Bowman ED, Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007 99 1257 1269
35. Ryan BM, Pine SR, Chaturvedi AK, Caporaso N, Harris CC., A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J Thorac Oncol 2014 9 1494 1503
36. Mathé EA, Patterson AD, Haznadar M, Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res 2014 74 3259 3270
37. Douillard JY, Tribodet H, Aubert D, LACE Collaborative Group Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 2010 5 220 228
38. Pignon JP, Tribodet H, Scagliotti GV, LACE Collaborative Group Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008 26 3552 3559
39. Strauss GM, Herndon JE 2nd, Maddaus MA, Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008 26 5043 5051
40. Butts CA, Ding K, Seymour L, Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010 28 29 34
41. Schlesinger Y, Straussman R, Keshet I, Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007 39 232 236
42. Widschwendter M, Fiegl H, Egle D, Epigenetic stem cell signature in cancer. Nat Genet 2007 39 157 158
43. Hassan KA, Chen G, Kalemkerian GP, Wicha MS, Beer DG., An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res 2009 15 6386 6390
44. Lindeman NI, Cagle PT, Beasley MB, Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013 8 823 859
45. Kikuchi J, Takashina T, Kinoshita I, Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 2012 78 138 143
46. Sato T, Kaneda A, Tsuji S, PRC2 overexpression and PRC2-Target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep 2013 3 1911
47. McCabe MT, Ott HM, Ganji G, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-Activating mutations. Nature 2012 492 108 112